AZ/Merck & Co take on Clovis as FDA approves prostate cancer drugThe FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator Share XAZ/Merck & Co take on Clovis as FDA approves prostate cancer drughttps://pharmaphorum.com/news/az-merck-cos-lynparza/
Clovis steals march on AZ with PARP prostate approvalShares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP Share XClovis steals march on AZ with PARP prostate approvalhttps://pharmaphorum.com/news/clovis-steals-march-on-az-with-parp-prostate-approval/
AZ and MSD’s Lynparza gets fast prostate cancer FDA reviewThe FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the Share XAZ and MSD’s Lynparza gets fast prostate cancer FDA reviewhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/
Clovis takes PARP prostate cancer pole position with fast FDA review of RubracaThe FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate Share XClovis takes PARP prostate cancer pole position with fast FDA review of Rubracahttps://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/
New price gets Clovis’ PARP inhibitor on the CDFNICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to Share XNew price gets Clovis’ PARP inhibitor on the CDFhttps://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/
ESMO 2019 roundupThe European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma Share XESMO 2019 rounduphttps://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/
Clovis signs radiopharmaceuticals R&D deal with German biotech 3BClovis Oncology has become the latest pharma to invest in radiopharmaceuticals, signing a licensing and collaboration deal with Share XClovis signs radiopharmaceuticals R&D deal with German biotech 3Bhttps://pharmaphorum.com/news/clovis-signs-radiopharmaceuticals-rd-deal-with-german-biotech-3b/
Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancerClovis Oncology’s Rubraca has become the latest PARP drug to show potential in pancreatic cancer, as pharma companies Share XClovis’ Rubraca is latest PARP drug showing promise in pancreatic cancerhttps://pharmaphorum.com/news/clovis-rubraca/
FDA says Clovis’ Rubraca could be prostate cancer breakthroughClovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving Share XFDA says Clovis’ Rubraca could be prostate cancer breakthroughhttps://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/
